Report : A-Z HCD items in Formulary 03/04/2025 13:01:42

[Back]

Section Status HCD Name 05.03.01 Formulary Abacavir  05.03.01 Formulary Abacavir and Lamivudine  06.06.01 Formulary Abaloparatide  10.01.03 Formulary Abatacept Orencia® 10.01.03 Formulary Adalimumab Biosimilars avaliable 13.05.03 Formulary Adalimumab Biosimilars avaliable 05.03.03 Formulary Adefovir Dipivoxil Hepsera® 11.08.02 Formulary Aflibercept Eylea® 13.05.01 Formulary Alitretinoin Toctino® 05.02 Formulary Amphotericin B (liposomal)  10.01.03 Formulary Anakinra Kineret® 05.02.04 Formulary Anidulafungin  13.05.03 Formulary Apremilast Otezla® 05.03.01 Formulary Atazanavir  05.03.01 Formulary Atazanavir sulfate and cobicistat Evotaz® 10.01.03 Formulary Baricitinib Olumiant® 10.01 Formulary Belimumab Benlysta® 03.04.02 Formulary Benralizumab Fasenra® 03.04.03 Formulary Berotralstat dihydrochloride Orladeyo® 11.08.02 Formulary Bevacizumab gamma  13.05.03 Formulary Brodalumab Kyntheum® 11.08.02 Formulary Brolucizumab  Beovu® 05.02.04 Formulary Caspofungin  10.01.03 Formulary Certolizumab Pegol Cimzia® 05.03.01 Formulary Darunavir  09.01.03 Formulary Deferasirox Exjade® 09.01.03 Formulary Deferiprone Ferriprox® 11.04.01 Formulary Dexamethasone intravitreal implant Ozurdex® 08.02.04 Formulary Dimethyl fumarate Tecfidera® 13.05.03 Formulary Dupilumab Dupixent® 05.03.01 Formulary Efavirenz  01.09.01 Formulary Elafibranor  09.01.04 Formulary Eltrombopag Revolade® 05.03.01 Formulary Emtricitabine Emtriva® 05.03.03 Formulary Entecavir  02.08.01 Formulary Epoprostenol  10.01.03 Formulary Etanercept Biosimilars avaliable 13.05.03 Formulary Etanercept Biosimilars avaliable 05.03.01 Formulary Etravirine Intelence® 11.08.02 Formulary Faricimab Vabysmo ® 08.02.04 Formulary Fingolimod  11.04.01 Formulary Fluocinolone intravitreal implant Iluvien® 05.03.01 Formulary Fostemsavir Rukobia® 05.03.02.02 Formulary Ganciclovir  10.01.03 Formulary Golimumab Simponi® 11.11 Formulary Holoclar  02.12 Formulary Inclisiran  Leqvio® 08.01 Formulary Infliximab  10.01.03 Formulary Infliximab Biosimilars avaliable 13.05.03 Formulary Infliximab Biosimilars avaliable 13.05.02 Formulary Ixekizumab  Taltz® 08.03.04.03 Formulary Lanreotide  09.05.02.02 Formulary Lanthanum Fosrenol ® 13.05.03 Formulary Lebrikizumab  08.03.04.03 Formulary Octreotide  08.03.04.03 Formulary Octreotide  13.05.03 Formulary Omalizumab  11.08.02 Formulary Ranibizumab  04.09.03 Formulary Riluzole Rilutek® 01.05.03 Formulary Risankizumab Skyrizi® 10.01.03 Formulary Risankizumab Skyrizi® 13.05.03 Formulary Risankizumab Skyrizi® 13.05.03 Formulary Ritlecitinib  08.02.03 Formulary Rituximab  09.01.03 Formulary Rituximab  09.01.04 Formulary Rituximab idiopathic thrombocytopenia in adults 10.01.03 Formulary Rituximab (rheumatology) Biosimilars avaliable 09.01.04 Formulary Romiplostim Nplate® 08.02.04 Formulary Ropeginterferon Alfa-2b Besremi® 10.01.03 Formulary Sarilumab Kevzara® 13.05.03 Formulary Secukinumab Cosentyx® 05.03.03.02 Formulary Sofosbuvir and Velpatasvir  Epclusa® 06.05.01 Formulary Somatropin  05.03.01 Formulary Tenofovir alafenamide, elvitegravir, cobicistat & emtricitabine  Genvoya® 06.06.01 Formulary Teriparatide  13.05.03 Formulary Tildrakizumab Ilumetri® 10.01.03 Formulary Tocilizumab Biosimilars avaliable 06.05.02 Formulary Tolvaptan  13.05.03 Formulary Ustekinumab Stelara® 08.01 Formulary Vedolizumab Entyvio® 11.11 Formulary Voretigene Neparvovec Luxturna®

Lancashire and South Cumbria